If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Badar, T., Hamadani, M., Bachanova, V., Maddocks, K. J., Umyarova, E., Chavez, J. C., Epperla, N., Chhabra, S., Xavier, A. C., Karmali, R., Salhab, M., Reddy, N., Glenn, M. J., Hernandez-Ilizaliturri, F. J., Flowers, C. R., Evens, A., Zhou, Z., Lansigan, F., Barta, S. K., Cohen, J. B. & 2 othersFenske, T. S. & Costa, L. J., Mar 21 2019, In : Leukemia and Lymphoma. 60, 4, p. 940-946 7 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Treatment Failure
Drug Therapy
B-Lymphocytes
Ifosfamide

Important new developments in Hodgkin Lymphoma

Evens, A., Jan 1 2019, In : British Journal of Haematology. 184, 1, 1 p.

Rutgers, The State University

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

Hill, B. T., Nastoupil, L., Winter, A. M., Becnel, M. R., Cerhan, J. R., Habermann, T. M., Link, B. K., Maurer, M. J., Fakhri, B., Reddy, P., Smith, S. D., Mukhija, D., Jagadeesh, D., Desai, A., Alderuccio, J. P., Lossos, I. S., Mehra, P., Portell, C. A., Goldman, M. L., Calzada, O. & 9 othersCohen, J. B., Hussain, M. J., Ghosh, N., Caimi, P., Tiutan, T., Martin, P., Kodali, A., Evens, A. & Kahl, B. S., Feb 1 2019, In : British Journal of Haematology. 184, 4, p. 524-535 12 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Follicular Lymphoma
Maintenance
Observation
Therapeutics
Vincristine

Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release

Sabhachandani, P., Sarkar, S., Mckenney, S., Ravi, D., Evens, A. & Konry, T., Feb 10 2019, In : Journal of Controlled Release. 295, p. 21-30 10 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Microfluidics
Lymphoma, Large B-Cell, Diffuse
Hydrogel
Biomarkers
Tumor Microenvironment
1 Citation (Scopus)

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

Sharman, J. P., Forero-Torres, A., Costa, L. J., Flinn, I. W., Inhorn, L., Kelly, K., Bessudo, A., Fayad, L. E., Kaminski, M. S., Evens, A., Flowers, C. R., Sahin, D., Mundt, K. E., Sandmann, T., Fingerle-Rowson, G., Vignal, C., Mobasher, M. & Zelenetz, A. D., Mar 21 2019, In : Leukemia and Lymphoma. 60, 4, p. 894-903 10 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Safety
Vincristine
Prednisone
Doxorubicin